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Abstract. 
 
During apoptosis, the cell actively dismantles 
itself and reduces cell size by the formation and pinch-
ing off of portions of cytoplasm and nucleus as “apop-
totic bodies.” We have combined our previously estab-
lished quantitative assay relating the amount of release 
of [
 
3
 
H]-membrane lipid to the degree of apoptosis with 
electron microscopy (EM) at a series of timepoints to 
study apoptosis of lymphoid cells exposed to vincristine 
or etoposide. We ﬁnd that the [
 
3
 
H]-membrane lipid re-
lease assay correlates well with EM studies showing the 
formation and release of apoptotic bodies and cell 
death, and both processes are regulated in parallel by 
inducers or inhibitors of apoptosis. Overexpression of 
Bcl-2 or inhibition of caspases by DEVD inhibited 
equally well the activation of caspases as indicated by 
PARP cleavage. They also inhibited [
 
3
 
H]-membrane 
lipid release and release of apoptotic bodies. EM 
showed that cells overexpressing Bcl-2 displayed near-
normal morphology and viability in response to vincris-
tine or etoposide. In contrast, DEVD did not prevent 
cell death. Although DEVD inhibited the chromatin 
condensation, PARP cleavage, release of apoptotic 
bodies, and release of labeled lipid, DEVD-treated 
cells showed accumulation of heterogeneous vesicles 
trapped in the condensed cytoplasm. These results sug-
gest that inhibition of caspases arrested the maturation 
and release of apoptotic bodies. Our results also imply 
that Bcl-2 regulates processes in addition to caspase ac-
tivation.
Key words: apoptosis • bcl-2 • chemotherapy • elec-
tron microscopy • lipids
 
A
 
POPTOSIS
 
 was recognized in the early 60’s when Kerr
and Wyllie described a form of cell death different
from necrosis (Kerr and Harmon, 1991). Apopto-
sis is an important process in normal development, tissue
homeostasis, immune responses and cancer pathogenesis
and treatment. Apoptotic cells show distinct morphologi-
cal features not found in necrotic cells, including mem-
brane blebbing, chromatin condensation, and cell shrinkage
(Kerr and Harmon, 1991). An important feature of apopto-
sis is the formation and release of apoptotic bodies: mem-
brane bound remnants of varying sizes containing cellular
organelles and/or fragments of chromatin. During the pro-
cess of apoptosis, cells dismantle themselves by packaging
cell remnants and condensed chromatin into apoptotic
bodies that are recognized and engulfed by neighboring
cells, thereby avoiding an inflammatory response charac-
teristic of necrosis (Kerr and Harmon, 1991). Although
formation of apoptotic bodies is accepted as a distinct fea-
ture of apoptosis, few studies coordinate biochemical and
ultrastructural studies of the process of apoptosis.
Several activators and inhibitors of apoptosis have been
studied, including Bcl-2 (Reed, 1997a) and the caspases
(Cohen, 1997), whose activities regulate the execution of
apoptosis. Bcl-2 is a 26-kD protein distributed in mito-
chondrial membranes, endoplasmic reticulum, and the nu-
clear envelope (Reed, 1994). Overexpressing Bcl-2 pro-
tects cells from apoptotic inducers including TNF-
 
a
 
, 
 
g
 
irradiation, serum deprivation and chemotherapeutic agents
such as vincristine and etoposide (Reed, 1994, 1997a).
Caspases are a family of cysteine-directed proteases in-
cluding 10 subgroups, each recognizing a distinct group
of substrates. Caspase 3 (CPP32/YAMA/Apopain) is acti-
vated in chemotherapy-induced apoptosis (Cohen, 1997).
Protein substrates of caspases include poly (ADP-ribosyl)
polymerase (PARP), lamins, retinoblastoma protein (
 
Rb
 
),
the 70-kD protein component of the U1 small ribonucleo-
protein, fodrin, and actin (Cohen, 1997).
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In addition to Bcl-2 and caspases, studies have impli-
cated mitochondrial function, ceramide and phospholipase
A
 
2 
 
(the enzyme that causes generation of arachidonic acid)
in the regulation of apoptosis (Dennis, 1994). In a previous
study evaluating the role of arachidonic acid (AA) and
phospholipase A
 
2
 
 in apoptosis (Zhang et al., 1998), we
demonstrated that the release of [
 
3
 
H]arachidonic acid (or
[
 
3
 
H]palmitic acid) during chemotherapy-induced apopto-
sis did not represent release of free fatty acid. Instead, re-
lease of [
 
3
 
H]-label reflected the release of intact mem-
brane lipids. The release of [
 
3
 
H]-labeled membrane lipids,
therefore, did not represent activation of the enzyme
PLA
 
2
 
 but probably represented release of membrane vesi-
cles and fragments.
Using this release assay we demonstrate here that
membrane lipid release is a regulated aspect of apoptosis
in lymphoid cells. Chemotherapy-induced membrane lipid
release is inhibited by Bcl-2 and by the caspase 3 inhibitor
peptide, DEVD. In contrast, cell death is inhibited by Bcl-2
but not by DEVD. EM shows several stages of apoptosis
and apoptotic body formation. EM demonstrates that
Bcl-2 inhibits all stages of apoptosis. In contrast, the cas-
pase inhibitor, DEVD, does not inhibit all morphologic as-
pects of apoptosis, but does inhibit the release of apoptotic
bodies as measured by biochemical assay and by EM stud-
ies. Thus, coupling membrane lipid release assay with elec-
tron microscopy allows new insight into the process of
apoptosis. These data implicate for the first time caspases
in the blebbing and pinching off of apoptotic bodies and
vesicles. The results also support a more generalized role
for Bcl-2 in regulating apoptosis that transcends inhibition
of caspases.
 
Materials and Methods
 
Cell Lines and Reagents
 
Pre-B leukemia cell line ALL-697 containing a mock vector (neo) or a
Bcl-2 overexpression vector (Bcl-2) were kindly provided by Dr. John
Reed (Burnham Institute, La Jolla, CA). T cell leukemia Molt-4
cells stably transfected with the vector carrying a hygromycin-resis-
tant cDNA or a murine Bcl-2 overexpression vector were also used in
this study (Zhang et al., 1996). Molt-4 and ALL-697 cell lines were
maintained in RPMI 1640 medium supplemented with 2.5% Hepes
buffer and 10% fetal bovine serum (GIBCO BRL). All experiments
were conducted under serum-free conditions. Vincristine (VCR) and
etoposide were purchased from Sigma Chemical Co. [
 
3
 
H]Arachidonic
acid  and [
 
3
 
H]palmitic acid were purchased from NEN™ Life Science
Products.
 
Measurement of Release of Radioactivity
 
Cells were seeded at 1.2 
 
3
 
 10
 
6 
 
cells/ml in serum-free medium and labeled
for 16 h with [
 
3
 
H]-labeled free fatty acid (1.5 
 
m
 
Ci/ml). The cells were
washed twice with sterile PBS (Sigma Chemical Co.), seeded at 5 
 
3
 
 10
 
5
 
cells/ml in serum-free medium, and treated under various conditions as in-
dicated in the text. The cells were collected in a microtube afterward and
resuspended evenly. Sample of 200 
 
m
 
l was counted and labeled as total
counts (A). The remaining cells in the microtube were pelleted at 2,000 
 
g
 
in a micro centrifuge for 5 min. The supernatant (200 
 
m
 
l) was transferred
to another scintillation vial, and the radioactivity was counted as the
amount of radioactivity release into the medium and termed B. The
amount of release of radioactivity was expressed as percentage of B over A.
 
Western Blot Analysis
 
Cells were seeded at 5 
 
3
 
 10
 
5
 
/ml in serum-free medium. Cells of 1 
 
3
 
10
 
6 
 
were treated under conditions indicated in the text, and were collected
and washed once with phosphate buffered saline (pH 7.4). These cells
were resuspended in the sample buffer. The whole cell extracts were
separated by 6% SDS-PAGE and transferred to a nitrocellulose
membrane. The membrane was blocked with 5% dry milk and de-
tected by anti-PARP antibody in a 1:2,000 dilution (Transduction
Laboratories).
 
Electron Microscopy
 
ALL-697 pre-B cell line with and without human Bcl-2 overexpres-
sion vector and Molt-4 T cells with and without murine Bcl-2 overex-
pression vectors were prepared for EM after 3, 6, 12, and 24 h of ex-
posure to the selected apoptotic inducer. Controls were identical cells
grown for the same length of time without the inducer. Cells were spun at
the relatively high speed of 2,000 
 
g
 
 for 5 min to pellet cell fragments as
well as intact cells (one set of experiments was conducted using a low
speed spin just sufficient to pellet the cells). Cell pellets were immediately
fixed at room temperature in 3% glutaraldehyde tousimis, 0.2% tannic
acid (Electron Microscopy Sciences) in 10 mM MOPS (3-[
 
N
 
-Mor-
pholino]propanesulfonic acid) buffered mammalian ringer, pH 7.2 for 30
min. After rinsing in buffered ringer and then in PO
 
4
 
 buffer, cells were
post fixed in 1% OsO
 
4
 
 (100 mM K
 
3
 
PO
 
4
 
, 10 mM MgCl
 
2
 
, pH 6.1) ice-cold
for 20 min. Cells were block-stained with 2% aqueous uranyl acetate for
30 min at room temperature after rinsing twice in water, and dehydrated
in a graded ethanol series 50–100% and embedded in Araldite 506 (Reedy
et al., 1988; Novak et al., 1995). Sections were cut with a diamond knife
on a Reichert OMU3 ultramicrotome and stained with KMnO
 
4
 
 and
lead (Reedy et al., 1988) and photographed on a Philips EM 420.
 
Trypan Blue Exclusion Experiments
 
Cells were seeded at 5 
 
3
 
 10
 
5
 
 cells/ml in RPMI 1640 serum-free medium.
After the indicated times of treatments under conditions, as indicated in
the text, cells were resuspended in 10 
 
m
 
l PBS, diluted at 1:1 ratio with Try-
pan Blue solution (0.4%; Sigma Chemical Co.). The dead and live cells
were counted using a hemocytometer.
 
Results
 
Caspase Inhibitors Inhibit Chemotherapeutic
Agent-induced Release of Membrane Lipid Release
 
To study the regulatory mechanism of chemotherapy-
induced apoptosis, we took advantage of the membrane
lipid release assay (Zhang et al., 1998). Pre-B cell leukemia
ALL-697 cells were prelabeled overnight with [
 
3
 
H]palmi-
tate and treated with etoposide (10 mM), alone or together
with either 60 
 
m
 
M Z-Asp-Glu-Val-Asp-CH
 
2
 
F (DEVD; an
irreversible inhibitor of caspase 3 and related caspases), or
the same concentration of N-Tyr-Val-Ala-Asp-aldehyde
(YVAD; a reversible inhibitor of caspase 1 and related
caspases). Fig. 1 A demonstrates that etoposide induced
release of [
 
3
 
H]palmitate in the form of membrane lipid
such that by 12 h there was more than twofold increase of
release of radioactivity as compared with control cells. In
contrast, in the presence of DEVD, the etoposide-induced
release of radioactivity was inhibited throughout the time
course evaluated, and remarkably, this inhibition contin-
ued up to 72 h of etoposide treatment. The inhibitor of
caspase 1, YVAD, could not effectively inhibit etoposide-
induced release of labeled membrane lipid in ALL-697
 
1. 
 
Abbreviations used in this paper: 
 
AA, arachidonic acid; DEVD,
Z-Asp-Glu-Val-Asp-CH
 
2
 
F; PARP, poly (ADP-ribosyl) polymerase; 
 
Rb
 
,
retinoblastoma protein; VCR, vicristine; Y VAD, N-Tyr-Val-Ala-
Asp-aldehyde. 
Zhang et al. 
 
Role for Caspases in Apoptotic Body Release
 
101
 
cells even at the earliest time point (12 h). We used both
reversible and irreversible forms of DEVD and YVAD in
this assay. Both forms of DEVD were inhibitory, whereas
neither form of YVAD was inhibitory (data not shown).
To establish the effective concentration for the caspase
inhibitors, we conducted a dose response study using vary-
ing concentrations of either DEVD or YVAD on the re-
lease of membrane lipids, as an indicator of release of
apoptotic bodies. DEVD or YVAD ranging from 1 
 
m
 
M to
100 
 
m
 
M were used. Fig. 1 B demonstrates that etoposide
treatment (10 
 
m
 
M) induced release of membrane lipids
within 6 h. The addition of YVAD up to 100 
 
m
 
M had no
effect on the release of membrane lipids. In contrast, the
addition of DEVD effectively inhibited the release of
membrane lipids at a concentration as low as 10 
 
m
 
M. At
50 
 
m
 
M, the release of membrane lipid was completely in-
hibited (Fig. 1 B). Thus, in the following experiments, we
chose 60 
 
m
 
M as our effective concentration of caspase in-
hibitor on the regulation of apoptosis induced by chemo-
therapeutic agents.
These results indicate that the release of membrane lip-
ids in chemotherapeutic agent-induced apoptosis could be
effectively inhibited by DEVD, the inhibitor of caspase 3.
 
Caspase Inhibitors, Unlike Bcl-2, Cannot Prevent
Cell Death
 
In an effort to understand the relationship between the re-
lease of labeled membrane lipids and cell death, we next
evaluated cell viability by Trypan Blue exclusion analysis.
ALL-697 cells transfected with Bcl-2 or with a vector car-
rying the neomycin gene (neo) were evaluated for viability
in response to etoposide (10 mM). Fig. 2 demonstrates
that cells overexpressing Bcl-2 no longer proliferated in
the presence of etoposide, but these cells were alive even
up to 72 h of etoposide treatment, as no dead cells were
present upon Trypan Blue exclusion analysis. In contrast,
cells transfected with vector control started to die as early
as 6 h, and by 24 h all the cells were dead.
On the other hand, despite the fact that DEVD blocked
membrane lipid release, it was unable to prevent cell
death. ALL-697 cells pretreated with DEVD (60 
 
m
 
M) and
then with etoposide initially displayed a slower rate of cell
death as measured by Trypan blue exclusion assay, but by
24 and 48 h cell death increased to the same level as the
cells that had not been exposed to DEVD (Fig. 2).
To demonstrate that cell death in response to etoposide
in the ALL-697 was indeed apoptotic and was mediated by
caspases, we next evaluated cleavage of the caspase 3 sub-
strate poly (ADP-ribose) polymerase (PARP). PARP was
cleaved from the intact 116-kD protein into the expected
85-kD proteolytic fragment after treatment with etoposide
at 12 h (Fig. 3). As expected, cells overexpressing Bcl-2
were protected from etoposide-induced PARP cleavage,
consistent with the lack of cell death seen in Fig. 2. Simi-
larly, the addition of DEVD almost completely protected
cells from PARP cleavage by 12 h, and significantly pro-
tected cells from PARP cleavage by 48 h. Under the same
Figure 1. The caspase inhibitor DEVD prevents membrane lipid
release induced by etoposide. ALL-697 cells were seeded at 1.2 3
106 cells/ml in serum-free RPMI 1640 medium. These cells were
pre-labeled with [3H]palmitic acid (see Materials and Methods).
The pre-labeled cells were seeded at 5 3 105 cells/ml in serum-
free medium, and treated under various conditions. At the indi-
cated time, samples (including medium and cells) were collected
and the released radioactivity was measured following the
method described in Materials and Methods. (A) Time course of
etoposide treatment. (B) Dose response of inhibitors DEVD and
YVAD.
Figure 2. DEVD, unlike Bcl-2, does not prevent loss of viability
by etoposide treatment. ALL-697 cells were seeded at 5 3 105
cells/ml in serum-free RPMI 1640 medium. These cells were
treated as described in the text, and the loss of cell viability was
measured using Trypan Blue exclusion assay. 
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condition, the cells were beginning to die by 12 h, and
were completely dead by 48 h. These data confirm that the
activation of caspase 3 and the related enzymes were sig-
nificantly inhibited by DEVD, but DEVD only slightly de-
layed but did not protect from cell death. Since DEVD in-
hibited membrane lipid release, these results also imply
that caspase 3 activity is required in the release of mem-
brane lipids.
Bcl-2 inhibits the process that initiates apoptotic body
formation whereas DEVD, the inhibitor of caspase, ar-
rests the subsequent maturation and release of apoptotic
bodies in chemotherapeutic agent-induced apoptosis.
To gain understanding of the processes involved in apop-
totic body formation and release, we next used EM to
identify the structures and materials associated with these
processes. Using high speed centrifugation (10,000 
 
g
 
 for 30
min), we pelleted all the components released into the me-
dium from either control or etoposide-treated cells. Our
previous studies showed that under high speed centrifuga-
tion, more than 80% of the radioactivity released from the
apoptotic cells could be pelleted. Thin section EM on the
10,000 
 
g
 
 pellet showed heterogeneous vesicles, membrane
fragments, condensed chromatin, and small debris con-
taining some recognizable portions of mitochondria and
parts of other organelles (Zhang et al., 1998). Hardly any of
these components were seen in the high speed pellet from
the control cells, or in Bcl-2 overexpressing cells treated
with etoposide. These studies indicated that the released
membrane lipid was probably incorporated into these het-
erogeneous cellular fragments. 
We next processed whole cells for EM in an effort to
capture and visualize the several stages in the process of
apoptotic body formation, and gain insight into the mecha-
nism by which membrane lipids are released. ALL-697
and Molt-4 cells carrying an empty vector or a Bcl-2 over-
expressing vector were fixed at a series of time points with
and without exposure to several apoptotic inducers. After
treatment, whole cells were centrifuged at 12,000 
 
g
 
 for 5
min and the cell pellet was fixed. In one experiment, we
used 2,000 
 
g
 
 for 5 min (just sufficient to pellet the cells)
and in all other experiments, we centrifuged cells at 12,000 
 
g
 
to ensure that as much of the material released from the
cells as possible would be brought down with the whole
cell pellet.
Consistent with the [
 
3
 
H]-membrane lipid release assay,
the extracellular space around cells treated with either
etoposide or vincristine showed grossly more debris, mem-
brane profiles, and vesicles than the untreated cells. Cells
undergoing apoptosis also showed membrane blebbing
(Figs. 4 B and 5 B). The apoptotic cells were different
from the untreated cells (Figs. 4 A and 5 A) in the follow-
ing aspects: (a) The cytoplasm of apoptotic cells contained
heterogeneous vesicles in significantly greater abundance
than the control cells. The vesicles were of varying sizes
and of varying content; luminal profiles varied from empty
to dense, amorphous to particulate. Frequently, the con-
tents of vesicles appeared to be in the process of being re-
leased from the apoptotic cells (Figs. 4 B and 5 B). There
was a class of lysosome-like vesicles (Fig. 6 A, arrowhead)
that were not seen in the untreated cells (Figs. 4 A and 5
A). (b) At early time points in apoptotic cells, the mito-
chondria were not disrupted, but at later time points, they
appeared to be in various stages of involution. In some
cases, it was clear that mitochondria were being converted
to mid-size vesicles containing an amorphous substance of
medium density (Fig. 4 B). (c) The release of vesicles
(Figs. 4 B, 5 B, and 6 C) and the formation of apoptotic
bodies (Fig. 6 A) were evident. Some of these cells were
clearly pinching off portions of themselves (Fig. 6 A).
These budding portions fit all the descriptions of apoptotic
bodies that include cytoplasm, vesicles, and fragmented
nucleus. At early time points (3 h, Fig. 6 B) after exposure
to apoptotic inducers, the majority of the cells showed
irregular shapes and the nuclei were polymorphic (lobu-
lated). Although the nuclear chromatin was denser than
control cells, complete condensation of chromatin was seen
more frequently at later time points (Figs. 5 B and 6 C). By
6 h of exposure to 10 
 
m
 
M etoposide, many cells showed
completely condensed chromatin with no visible sub-struc-
ture and the surrounding cytoplasm was pale and granular,
without organelles (Fig. 6 C). These cells were classic apop-
totic cells.
Cells overexpressing Bcl-2 (Figs. 4 C and 5 C) responded
differently to inducers of apoptosis from untreated cells
(Figs. 4 A, 5 A, and Table I). Consistent with the experi-
ments on release of [
 
3
 
H]-membrane lipids, there were no
apoptotic bodies formed in the Bcl-2–transfected cells.
The extracellular space around the treated Bcl-2 cells was
clean, with no heterogeneous vesicles, organelle debris, or
electron dense substances. There was no recognizable
change in the morphology of the nucleus compared with
the control cells, i.e., chromatin condensation was inhib-
ited completely, consistent with previous reports (McCar-
thy et al., 1997). However, some large vesicles with dense
contents that appeared similar to lysosomal vesicles, seen
in apoptotic cells, also appeared in the Bcl-2 cells exposed
to vincristine or etoposide (Figs. 4 C, 5 C, and Table I).
The overall morphology of Bcl-2 cells under vincristine
and etoposide treatment was similar to that of untreated
Bcl-2 cells and untreated control cells.
The effects of the protease inhibitor DEVD on the mor-
phology of treated cells were quite different from that of
Figure 3. DEVD prevents PARP cleavage for up to 48 h. ALL-
697 cells were seeded at 6 3 105 cells/ml in serum-free RPMI
1640 medium. These cells were treated under various conditions
indicated in the text. At the indicated times the cells were har-
vested and suspended in 40 ml homogenizing buffer (50 mM Tris-
HCl, pH 7.4, 20 mM EDTA, pH 7.4; 10 mM EGTA, and 20 mg/ml
PMSF). These cells were resuspended in 23 sample buffer,
boiled for 10 min, and loaded on 7.5% SDS-PAGE. The Western
blot analysis was performed using rabbit anti–human PARP anti-
body. 
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Bcl-2 overexpression. We treated the cells with DEVD
alone or in combination with vincristine or etoposide. In
cells treated with DEVD alone, the cells looked identical
to the control cells (data not shown). When the cells were
treated with vincristine or etoposide in the presence of
DEVD (Figs. 4 D and 5 D), their morphology changed
dramatically. The extracellular space around the cells
treated with chemotherapeutic agent plus DEVD was much
cleaner than the cells treated with chemotherapeutic agent
alone. Also, there were no broken vesicles surrounding
the cell membrane. The major features of a typical re-
sponse were: (a) Many cells treated with vincristine and
DEVD became shrunken and had dark, condensed cyto-
plasm. The cells showed membrane-bound finger-like pro-
jections. (b) Abundant accumulation of various vesicles
crowded the condensed cytoplasm, suggesting that these
vesicles were trapped inside the cells. (c) The caspase
inhibitor DEVD did prevent complete condensation of
chromatin into dense pools; chromatin in the nuclei re-
mained recognizable as dark masses against a somewhat
lighter background. There was no fragmented chromatin
in the presence of DEVD. However, contrary to what was
expected, nuclei and chromatin appeared more dense and
compacted than normal (Table II and Figs. 4 D and 5 D vs.
Figs. 4 A and 5 A).
The great density and shrinkage of the DEVD cells and
the crowding of the remaining cytoplasm with accumula-
tions of various vesicles, and the lack of apoptotic bodies
in the extracellular space suggested that cells were begin-
ning the process of formation of apoptotic bodies. How-
Figure 4. Electron micro-
graphs comparing the effects
of DEVD and Bcl-2 on the
morphological changes of
ALL-697 cells treated with
chemotherapeutic agent. (A)
Untreated ALL-697 cells
show very few vesicles, a
rather uniform rounded
shape and no condensation
of nuclear chromatin. Typi-
cally, the extracellular space
shows little debris. (B) ALL-
697 cells treated with 1 mM
vincristine for 6 h. A typical
apoptotic cell showing some
chromatin condensation
around the periphery of the
nucleus and numerous vesi-
cles, several of which appear
to be releasing to the extra-
cellular space (arrows). (C)
After 6 h of 1 mM vincristine
treatment, ALL-697 Bcl-2
cells show only a few lyso-
somal-type vesicles (black
and white arrowhead) in the
cytoplasm, and some cells
show clear vesicles at the cell
surface (arrows); in contrast
to the releasing vesicles in
apoptotic cells (B), these
cells have a relatively thick
strand of cytoplasm still sepa-
rating them from the extra-
cellular space. (D) ALL-697
cells treated with 1 mM vin-
cristine in the presence of
DEVD (60 mM). Morpho-
logic changes include partial
condensation of chromatin
and a striking accumulation
of various vesicles in the cy-
toplasm. The overall conden-
sation of both cytoplasm and
nucleus caused shrinkage of
cell size compared with the
untreated cells. Heterogeneous vesicles are present and dense lysosomal vesicles are seen in cells labeled 2 as well as cells that are very
dark and shrunken labeled 3 and 4. Note that the cell surface shows finger-like projection and the extracellular space is relatively clean. 
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ever, the inhibition of caspase activation apparently ar-
rested the formation of apoptotic bodies in a intermediate
stage (Figs. 4 D and 5 D). This “intermediate stage” of
apoptosis distinguished itself from other stages of apop-
totic body formation by the apparent intracellular accu-
mulation of various vesicles in the condensed cytoplasm.
Comparison of Figs. 4 B vs. 4 D and 5 B vs. 5 D, together
with our studies on membrane lipid release (Zhang et al.,
1998) suggested that the heterogeneous vesicles that ap-
pear to accumulate in the cytoplasm of the cells treated
with DEVD and chemotherapeutic agents are possible
precursors of apoptotic bodies normally released in the ex-
tracellular space.
The regulatory role of DEVD on the formation of apop-
totic bodies suggested to us that the formation of apop-
totic bodies is a multi-staged process. Thus, we sequen-
tially investigated the stages of apoptotic body formation
by studying the cellular morphological changes at various
time points (3, 6, and 24 h) in response to treatment of
chemotherapeutic agents (Fig. 6). The various stages of
apoptotic body formation can be best illustrated in Fig. 6
A (stage 1 though stage 4). The early stage of apoptotic
body formation is characterized by the initial condensa-
tion of chromatin (Fig. 6 A, labeled 1). In this initial phase,
the overall structure of chromatin is still recognizable, al-
though compared with the normal nucleus (Fig. 4 A), the
chromatin is already somewhat condensed. The cell mem-
brane is intact at this stage. The next stage (Fig. 6 A, la-
beled 2) shows the intermediate stage of apoptotic body
formation, where various vesicles are formed and their
contents are being released into the extracellular space, to-
gether with the striking condensation of chromatin. Clearly,
the activation of caspases is required in the intermediate
step between the formation of heterogeneous vesicles and
the release of apoptotic bodies. The final stages of apop-
totic body formation are illustrated in Fig. 6 A (labeled 3
and 4), where the cells appear as ghost structures in which
all vesicles and apoptotic bodies have been released and
the cytosol is uniformly granular and only a small dense
pool indicates the former nucleus. At this stage, the extra-
cellular space is littered with granular ghosts of cells that
completed apoptosis at earlier times. In fact, at this late
Figure 5. Electron micro-
graphs comparing the effects
of Bcl-2 and DEVD on the
morphological changes of
Molt-4 T cells to etoposide.
(A) Untreated Molt-4 cells
display a rather uniform
rounded shape and no con-
densation of chromatin.
There were very few vesicles
in the cytoplasm of the cells.
Typically, the extracellular
space shows little debris. (B)
Molt-4 T cells after 14 h ex-
posure to etoposide show
many vesicles, some of which
are releasing to the medium
and a classic apoptotic nu-
cleus with completely con-
densed chromatin. (C) After
14 h exposure to etoposide,
Molt-4 Bcl-2 cells appear
identical to untreated control
cells. Note that the extracel-
lular space is clean. (D)
Caspase inhibition produces
strikingly condensed cells
overall, but nuclear chroma-
tin is only partly condensed
(compare to cells in B), the
remaining cytoplasm is
crowded with vesicles (ar-
rows). Finger-like projections
are prominent at the cell sur-
face. 
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stage, the cells resembled those described by Wyllie and
Kerr as “secondary necrosis,” probably since “in vitro” the
dead cells are not absorbed by surrounding cells. These
stages of apoptosis are also illustrated in the time course of
treatment (Fig. 6, B–D). Fig. 6 B shows the typical cell
morphology after 3 h of etoposide treatment, as chromatin
condensation has already started at this time (arrow).
After 6 h of etoposide treatment, various vesicles have
formed in the cytoplasm, combined with the striking con-
densation of chromatin (Fig. 6 C). After 24 h of vincristine
treatment (Fig. 6 D) or etoposide (data not shown), apop-
totic cells have completed the release of apoptotic bodies,
and the ghost structure of cells are the only remnants.
An interesting observation is that cells that had entered
mitosis appeared not to be affected by vincristine, since af-
ter 24 h of vincristine treatment, the only surviving cells
were those that had entered mitosis (Fig. 6 D). These sur-
viving mitotic cells were numerous in vincristine-treated
cells, but appeared far fewer in the presence of etoposide,
possibly as a result of the effects of vincristine on G
 
2
 
/M
progression.
Comparing the response of cells overexpressing Bcl-2 to
cells treated with DEVD suggested to us that multiple fac-
tors regulate the initiation, maturation, and release of apop-
totic bodies. The overexpression of Bcl-2 totally inhibited
the formation of apoptotic bodies. Compared with control
cells, the Bcl-2 cells appeared normal even under electron
microscopy after exposure to vincristine and etoposide for
extended times. There was no accumulation of vesicles or
fragmentation of chromatin in Bcl-2 cells in the presence
of chemotherapeutic agents, as an early indicator of the
formation of apoptotic bodies. More importantly, treated
Bcl-2 cells maintained their viability for a long time. On
the other hand, the inhibitor of caspases could not totally
reverse the process of the formation of apoptotic bodies.
However, DEVD interfered with the later stage of apop-
totic body formation by inhibiting the release of apoptotic
bodies, leading to the accumulation of various vesicles in-
side the cells and somewhat condensed chromatin. There-
fore, the activation of caspases appears to be a necessary
step in the subsequent maturation and release of apoptotic
bodies.
Overall, our studies demonstrate that formation of
apoptotic bodies is a multi-staged process, characterized
by the appearance of heterogeneous vesicles as the possi-
ble precursor of apoptotic bodies. Bcl-2 and the inhibitor
of caspases differentially regulate the process of apoptotic
body formation. Overexpression of Bcl-2 protein acts up-
stream of apoptotic body formation by completely inhibit-
ing the initiation of this process, whereas the inhibition of
caspase only inhibited the later stage of apoptotic body re-
lease.
 
Discussion
 
This study demonstrates that the formation of apoptotic
bodies is a multi-staged process that is regulated differen-
tially by Bcl-2 and caspases. Since the results clearly distin-
guish the action of Bcl-2 from that of caspases, they sug-
gest that the effects of Bcl-2 transcend the regulation of
caspases. In essence the results argue against proposed uni-
tary pathways whereby Bcl-2 functions primarily to regu-
late caspases.
This study reveals several differences between Bcl-2 and
 
Table I. Morphometric Analysis of EM Data
 
Vector Bcl-2
Control Vcr (6 h) Vcr (12 h) Vcr (24 h) Control Vcr (6 h) Vcr (12 h) Vcr (24 h)
 
Number of cells counted 23 50 18 39 14 54 33 23
Number of apoptotic cells 0 20 13 37 0 0 0 0
% Apoptotic cells 0 40 72 95 0 0 0 0
Number of vesicles counted 47 367 210 All released 39 133 84 49
Vesicles per cell 2.04 7.34 11.67 2.78 2.46 2.50 2.13
Number of apoptotic bodies 0 34 35 74 0 0 0 0
Apoptotic bodies per cell 0 0.68 1.94 1.90 0 0 0 0
 
Time course of Vcr (1 
 
m
 
M) meanment of ALL-697 cells stably transferred with vector or Bcl-2.
 
Table II. Morphometric Analysis of EM Data for Effects of DEVD on ALL-697 Cells Treated with Etoposide
 
Control Etoposide (3 h) Etoposide 
 
1 
 
DEVD (3 h) Etoposide (6 h) Etoposide 
 
1 
 
DEVD (6 h)
 
Number of cells counted 100 53 64 100 44
Number of apoptotic cells 0 23 21 76 31
% Apoptotic cells 0 43 33 76 70
Number of vesicles counted 52 227 284 417 670
Vesicles per cell 0.52 4.28 4.44 4.17 15.23
Number of apoptotic bodies 0 12 4 238 14
Apoptotic bodies per cell 0 0.23 0.06 2.38 0.32
Cytosolic density* 61 
 
6
 
 8 121 
 
6
 
 5 130 
 
6
 
 7 87 
 
6
 
 8 124 
 
6
 
 14
Chromatin density* 61 
 
6
 
 6 123 
 
6
 
 4 155 
 
6
 
 7 141 
 
6
 
 5 136 
 
6
 
 14
 
*Arbitrary units based on analysis using NIH Image Software: The EM pictures were scanned into TIFF image, 30 areas were randomly selected in the nucleus and cytosol of the
chromatic condensed cells and their average density measured. The results are the averages of these numbers with standard error of mean. 
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caspases in regulating apoptosis. First, Bcl-2 prevents the
loss of viability in chemotherapy-induced apoptosis, but
inhibitors of caspases do not. Second, Bcl-2 prevents most
of the manifestation of apoptosis at the ultrastructural
level, as shown by the near normal appearance of cells
in response to chemotherapeutic agent-treatment whereas
caspase inhibitors fail to inhibit many features of apopto-
sis, including cell volume loss and chromatin condensa-
tion. Third, Bcl-2 prevents the formation of apoptotic bod-
ies completely, whereas caspase inhibitors do not interfere
with the initial process that lead to apoptotic body forma-
tion, but DEVD clearly inhibits release of apoptotic bod-
ies and vesicles.
These results have several important implications in cur-
rent research on apoptosis. EM studies reveal several
phases of apoptosis and apoptotic body formation. Upon
induction of apoptosis, the cells enter the initial phase of
apoptotic body formation by the beginning of the conden-
sation of chromatin. In this initial phase, the overall struc-
ture of chromatin is still recognizable, although compared
with the normal nucleus, the chromatin is already some-
what condensed. The cells enter the intermediate stage of
Figure 6. The various phases
of apoptotic body formation
in chemotherapeutic agent-
treated ALL-697 cells. (A)
ALL-697 cells were treated
with 10 mM etoposide for 6 h.
Various phases of the forma-
tion of apoptotic bodies are
evident in this micrograph
and are labeled 1–4. The cell
labeled 1 is at an early stage
and shows very minimal
chromatin condensation in the
nucleus (Nu), but an apop-
totic body (AP) can be seen
budding off and another is
probably forming adjacent to
it. The cell labeled 2 is at an
intermediate stage and shows
partially condensed chroma-
tin in the nucleus, apoptotic
body formation and many
heterogeneous vesicles (V).
The black and white arrow-
head points to a vesicle with
dense contents that suggests
lysosomal origin. The small
arrow points to one vesicle
that appears poised to open
and release to the extracellu-
lar space, which is full of
membrane profiles and de-
bris, characteristic of cells ex-
posed to apoptotic inducers.
The cells labeled 3 and 4
have completed apoptosis
and are dispersing as granu-
lar debris (the ghost cell
stage). This images clearly
demonstrates that induction
of apoptosis is asynchro-
nous. (B) The typical mor-
phological changes of the
cells after 3 h treatment with
10 mM etoposide. The arrow
indicates the beginning of
chromatin condensation at
the periphery of the nucleus.
Of note is that at the early phase of apoptotic body formation, there is not much accumulation of vesicles in the cells. (C) The typical
morphological changes of the cells after 6 h treatment with 10 mM etoposide (middle stage). At this stage, the chromatin condensation
is very striking, with various vesicles (V) forming and releasing their contents into the extracellular space (arrow). At this stage, the cells
are still intact. (D) Typical morphological changes of the cells after 24 h treatment with 1 mM vincristine (latest stage). At this stage, the
cellular contents are totally released from the cells, with only ghost cells (arrow) and totally condensed chromatin remaining. Nu, con-
densed nuclear remnant of ghost cell. Black arrowhead indicates surviving cell in mitosis. 
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apoptotic body formation by forming heterogeneous vesi-
cles in the cytoplasm and release these vesicles into the ex-
tracellular space. By this time, the chromatin is condensed
to such an extent that no structure could be recognized.
The nucleus is fragmented into several pieces. In the final
stage of apoptosis, the cells appear as ghost structures in
which all vesicles and apoptotic bodies have been released
and the cytosol is uniformly granular and only a small
dense pool indicates the former nucleus.
This three-phase apoptotic process is regulated at least
at two levels: Bcl-2 prevents the initiation of the first phase,
whereas caspase inhibitors do not interfere with the initia-
tion of the apoptotic program leading to the accumulation
of precursor vesicles, but do prevent the release of apop-
totic bodies from apoptotic cells (Fig. 7).
Our study also shows that Bcl-2, compared with DEVD,
acts at a proximal step in the apoptotic pathway and that
Bcl-2 can maintain cell viability, although it fails to main-
tain the cells’ ability to proliferate. Therefore, Bcl-2 acts
upstream of the “commitment site” in apoptosis. In con-
trast, activation of caspases in chemotherapy-induced
apoptosis acts at a point downstream of the commitment
step, as inhibition of caspase activity cannot prevent loss of
cell viability.
This divergence of the action of Bcl-2 and caspases
raises interesting questions about the mechanism of action
of Bcl-2 and its relation to caspases: although Bcl-2 has
been studied extensively in apoptosis, the exact point at
which Bcl-2 works to regulate the apoptotic program is
still poorly defined. Bcl-2 has been found to interfere with
the apoptotic pathway at a point upstream of caspases, in-
hibiting caspase activation upon induction of apoptosis
(Yuan, 1995). Activation of caspases could also be initi-
ated by cytochrome c, another important regulator of
apoptosis (Reed, 1997b). Recent studies suggest that dur-
ing apoptosis, cytochrome c is released from the mitochon-
dria to the cytosol, and that the increased accumulation of
cytochrome c in the cytosol triggers caspase activation. In
addition, based on in vitro studies (Li et al., 1997), it was
shown that cytochrome c could trigger caspase activation
directly by forming a protein complex with Apaf 1 (the hu-
man homologue of ced-4), and Apaf 3 (caspase 9; Li et al.,
1997). Overexpression of Bcl-2 has been shown to prevent
the release of cytochrome c in apoptosis (Yang et al., 1997;
Kluck et al., 1997), implying that Bcl-2 acts upstream of
the release of cytochrome c in apoptosis. Thus, it has been
proposed that Bcl-2 acts primarily to inhibit the release of
cytochrome c from mitochondria and the consequent acti-
vation of caspases (Kluck et al., 1997;  Yang et al., 1997).
These and other results have led to the hypothesis that
caspases are the primary executors of apoptosis and that
Bcl-2 functions primarily to interfere with caspase activa-
tion. The results from our study argue against this simpli-
fied model for the regulation of apoptosis, at least in che-
motherapy-induced apoptosis in lymphoid cells. Whereas
Bcl-2 prevents chemotherapy-induced death, DEVD only
inhibits a subset of the manifestations of apoptosis. Thus,
Bcl-2 not only acts upstream of caspases, but must also act
upstream of other non-caspase effectors of the apoptotic
program. Our results are compatible with either of two
scenarios: Bcl-2 may function primarily to inhibit cyto-
chrome c release. In this case, the release of cytochrome c
causes both activation of caspases required for release of
apoptotic bodies and activation of other unknown effec-
tors involved in initiation of the apoptotic program (the
early phases of apoptotic body formation; Fig. 7 A). Alter-
natively, Bcl-2 may inhibit a distinct pathway that activates
early events in apoptosis (Fig. 7 B) in addition to inhibiting
activation of caspases by cytochrome c (Kluck et al., 1997;
Yang et al., 1997).
This study also raises some important considerations as
to the role of caspases in chemotherapy-induced apopto-
sis: (a) caspase inhibitors do not prevent cell death in re-
sponse to etoposide or vincristine, but they inhibit some of
the manifestations of cell death such as PARP cleavage,
the release of membrane lipids as the indication of pinch-
ing off apoptotic bodies and vesicle release, and partially
inhibit the condensation of chromatin. This suggests that
caspases are restricted to an execution role. (b) An initial
regulatory role for caspases in chemotherapy-induced apop-
tosis is unlikely to be very significant, as once caspases are
activated, the cells have already passed the commitment
step in apoptosis. For example, inhibitors of caspases are
not expected to ameliorate chemotherapy induced toxicity
and side effects.
While studying the role of caspases in apoptosis induced
by Bak and DNA-damaging agents, McCarthy et al.
(1997) showed that the caspase inhibitors ZVAD.fmk and
BD.fmk could inhibit several aspects of cell death but
could not inhibit membrane blebbing. The failure to in-
hibit membrane blebbing caused eventual cell death. In
our studies, we have found that DEVD inhibits cellular
blebbing effectively (Figs. 4 D and 5 D). It is possible that
this difference is due to using different cells (they used
Rat-1 fibroblasts where as we used leukemia cells). There-
fore, we cannot further relate their observations to ours.
Xiang et al. (1996) showed that in Bax-induced apoptosis,
the treatment of protease inhibitors partially inhibited
the condensation of chromatin and what they termed as
“membrane vacuolation,” a process similar to what we de-
Figure 7. Proposed scheme
of Bcl-2 regulation of chemo-
therapy-induced apoptosis. 
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scribe as the intermediate stage of apoptotic body forma-
tion. All these studies however lend support to the notion
that caspases have a role only in the execution phase of
apoptosis, and after the commitment point has been
passed in the signal transduction pathway in apoptosis.
Finally, these observations show that care has to be
exercised in interpreting specific assays in the evaluation
of apoptosis. In chemotherapy-induced apoptosis in lym-
phoid cells, caspase inhibitors prevent PARP proteolysis,
membrane release, and many nuclear changes, but they
clearly do not inhibit ultimate cell death or changes in
overall cell morphology and nuclear structure. Therefore,
these observations underscore the importance of distin-
guishing the protection of cell viability from the inhibition
of downstream events in apoptosis, such as chromatin con-
densation, and PARP cleavage.
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